NCT Registry Reference

Clinical Trial Tracker

Browse 329 ClinicalTrials.gov entries across all compounds in the library. Filter by compound, trial phase, and status. Direct links to full NCT records. Data sourced from the ClinicalTrials.gov public API.

Research reference only. Trial data is sourced from ClinicalTrials.gov and may not reflect the most current registry status. Always verify directly on ClinicalTrials.gov before citing in research. Full disclaimer.

302

Total Trials

159

Completed

Active / Recruiting

Compounds Covered

302 results

NCT00267527TerminatedPh 2CJC-1295

A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity

n=120ClinicalTrials.gov ↗

Start: 2005-12Completion: 2006-09

Study Interventions

• CJC 1295

NCT00672074CompletedPh 2Ipamorelin

Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus

n=117ClinicalTrials.gov ↗

Start: 2008-04Completion: 2009-12

Study Interventions

• IV

NCT01280344CompletedPh 2Ipamorelin

Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

n=320ClinicalTrials.gov ↗

Start: 2011-04Completion: 2014-05

Study Interventions

• Intravenous (IV)

NCT01359488CompletedPh 1Sermorelin

VRS-317 in Adult Subjects With Growth Hormone Deficiency

n=50ClinicalTrials.gov ↗

Start: 2011-03Completion: 2012-07

Study Interventions

• VRS-317 Single Dose

• VRS-317 Single dose

NCT02931474WithdrawnPh 2Sermorelin

Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia

0ClinicalTrials.gov ↗

Start: 2016-10-06Completion: 2017-03-08

Study Interventions

• Growth Hormone-Releasing

NCT01701973CompletedPh 4Sermorelin

Effect of DPP4 Inhibition on Growth Hormone Secretion

n=44ClinicalTrials.gov ↗

Start: 2013-01Completion: 2017-05

Study Interventions

• During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)

• During Aim 2, given during one of two study days (Group C subjects only)

• During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.

• During Aim 2, given during one of two study days (Group A subjects only)

NCT03226821CompletedPh 4Sermorelin

Body Composition and Adipose Tissue in HIV

n=5ClinicalTrials.gov ↗

Start: 2018-02-07Completion: 2025-04-30

Study Interventions

• Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily

NCT06554717RecruitingPh 2Sermorelin

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

n=100ClinicalTrials.gov ↗

Start: 2025-07-07Completion: 2028-12-01

Study Interventions

• Home-based semi-supervised exercise program

• Tesamorelin WR 1.28 mg given subcutaneously daily

NCT00004332CompletedSermorelin

Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly

n=148ClinicalTrials.gov ↗

Start: 1993-05

NCT01897844CompletedPh 1Sermorelin

A Two Part Phase 1, Repeated Doses and Continuous Infusion Study With ITF2984 in Healthy Volunteers

n=36ClinicalTrials.gov ↗

Start: 2013-05Completion: 2013-12

Study Interventions

• ITF2984 (100, 2000, 3000 mcg bid)

NCT02271282CompletedPh 1Sermorelin

Estradiol-Receptor Blockade in Older Men and Women

n=40ClinicalTrials.gov ↗

Start: 2014-12Completion: 2016-05

Study Interventions

• Toremifene

• GHRH/Ghrelin combined Injection

NCT02736591UnknownPh 3Sermorelin

Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian Response

n=210ClinicalTrials.gov ↗

Start: 2016-06

Study Interventions

• Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering

• Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI.

NCT01788462WithdrawnSermorelin

Egrifta Replacement and Sleep Disordered Breathing

0ClinicalTrials.gov ↗

Start: 2012-05

Study Interventions

• We will observe the effects of Tesamorelin on patients with HIV and lipodystrophy.

NCT02931474WithdrawnPh 2Tesamorelin

Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia

0ClinicalTrials.gov ↗

Start: 2016-10-06Completion: 2017-03-08

Study Interventions

• Growth Hormone-Releasing

NCT03226821CompletedPh 4Tesamorelin

Body Composition and Adipose Tissue in HIV

n=5ClinicalTrials.gov ↗

Start: 2018-02-07Completion: 2025-04-30

Study Interventions

• Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily

NCT06554717RecruitingPh 2Tesamorelin

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

n=100ClinicalTrials.gov ↗

Start: 2025-07-07Completion: 2028-12-01

Study Interventions

• Home-based semi-supervised exercise program

• Tesamorelin WR 1.28 mg given subcutaneously daily

NCT01788462WithdrawnTesamorelin

Egrifta Replacement and Sleep Disordered Breathing

0ClinicalTrials.gov ↗

Start: 2012-05

Study Interventions

• We will observe the effects of Tesamorelin on patients with HIV and lipodystrophy.

NCT03150511RecruitingPh 2Tesamorelin

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

n=36ClinicalTrials.gov ↗

Start: 2018-06-01Completion: 2027-12

Study Interventions

• Daily self-administered study drug

NCT02012556CompletedPh 1Tesamorelin

Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients

n=18ClinicalTrials.gov ↗

Start: 2008-05Completion: 2008-07

Study Interventions

• Tesamorelin

NCT00608023CompletedPh 3Tesamorelin

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

n=263ClinicalTrials.gov ↗

Start: 2007-08Completion: 2008-10

Study Interventions

• Tesamorelin

NCT01632592WithdrawnNATesamorelin

Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue

0ClinicalTrials.gov ↗

Start: 2014-01Completion: 2014-01

Study Interventions

• The Growth Hormone Releasing Hormone analogue tesamorelin, 2mg subcutaneously daily by injection

NCT00675506CompletedPh 2Tesamorelin

Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

n=60ClinicalTrials.gov ↗

Start: 2008-07Completion: 2012-01

Study Interventions

• 2-mg sub-cutaneous injections once daily for 12 months

NCT02572323CompletedPh 2Tesamorelin

Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

n=73ClinicalTrials.gov ↗

Start: 2017-02-15Completion: 2023-10-15

Study Interventions

• Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV

NCT00074529CompletedPh 2MK-677

Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

n=512ClinicalTrials.gov ↗

Start: 2003-10Completion: 2006-01

Study Interventions

• MK0677

NCT05364684CompletedPh 2MK-677

The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease

n=12ClinicalTrials.gov ↗

Start: 2022-08-10Completion: 2024-12-23

Study Interventions

• LUM-201 (ibutamoren mesylate) is an oral growth hormone secretagogue.

NCT00474279CompletedPh 1Ph 2MK-677

Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults

n=72ClinicalTrials.gov ↗

Start: 1998-07Completion: 2004-06

Study Interventions

• Orally active growth hormone secretagogue (MK-677)

NCT01343641WithdrawnPh 2MK-677

Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects

0ClinicalTrials.gov ↗

Start: 2009-03Completion: 2010-04

Study Interventions

• The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck \& Co, Inc.

NCT06948214RecruitingPh 3MK-677

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

n=150ClinicalTrials.gov ↗

Start: 2026-04Completion: 2028-01

Study Interventions

• 1.6 mg/kg/day, administered orally once daily

NCT00116129CompletedPh 2MK-677

Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia

n=64ClinicalTrials.gov ↗

Start: 2005-07Completion: 2008-04

Study Interventions

• Ibutamoren Mesylate 25 mg/day

NCT00128115TerminatedPh 2MK-677

Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

n=83ClinicalTrials.gov ↗

Start: 2005-09Completion: 2007-08

Study Interventions

• MK0677

NCT00395291CompletedNAMK-677

Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients

n=49ClinicalTrials.gov ↗

Start: 2006-08Completion: 2010-05

Study Interventions

• The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.

NCT01395914CompletedPh 3Anamorelin

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

n=513ClinicalTrials.gov ↗

Start: 2011-07Completion: 2015-02

Study Interventions

• Anamorelin HCl

NCT04844970TerminatedPh 2Anamorelin

Anamorelin Study for Advanced Pancreatic Cancer

n=4ClinicalTrials.gov ↗

Start: 2023-04-01Completion: 2023-11-07

Study Interventions

• Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects.

NCT00622193CompletedPh 2Anamorelin

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

n=228ClinicalTrials.gov ↗

Start: 2008-03Completion: 2009-12

Study Interventions

• 50 mg tablet

• 100 mg tablet

NCT03743051CompletedPh 3Anamorelin

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

n=318ClinicalTrials.gov ↗

Start: 2019-03-05Completion: 2023-02-11

Study Interventions

• 100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)

NCT01387282CompletedPh 3Anamorelin

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)

n=495ClinicalTrials.gov ↗

Start: 2011-07Completion: 2015-02

Study Interventions

• Anamorelin HCL 100 mg will be orally administered daily at least 1 hour prior to meal

NCT03637816Active Not RecruitingPh 2Ph 3Anamorelin

Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer

n=25ClinicalTrials.gov ↗

Start: 2018-11-27Completion: 2026-12-31

Study Interventions

• Ancillary studies

• Given PO

NCT03035409Active Not RecruitingPh 2Anamorelin

Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors

n=129ClinicalTrials.gov ↗

Start: 2017-02-08Completion: 2026-02-28

Study Interventions

• Correlative studies

• Undergo nutritional counseling

• Undergo physical activity

• Ancillary studies

• Given PO

NCT03743064CompletedPh 3Anamorelin

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

n=318ClinicalTrials.gov ↗

Start: 2019-05-06Completion: 2022-12-27

Study Interventions

• 100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)

NCT01387269CompletedPh 3Anamorelin

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)

n=484ClinicalTrials.gov ↗

Start: 2011-07Completion: 2015-02

Study Interventions

• Anamorelin HCl will be orally administered daily at least one hour before meal

NCT01505764TerminatedPh 2Anamorelin

The Role of Ghrelin in Cancer Cachexia

n=10ClinicalTrials.gov ↗

Start: 2012-06Completion: 2016-03

Study Interventions

• 100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.

NCT02637284UnknownPh 1BPC-157

PCO-02 - Safety and Pharmacokinetics Trial

n=42ClinicalTrials.gov ↗

Start: 2015-10Completion: 2016-03

Study Interventions

• Phase 1a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-02 containing 1 mg of Bepecin to study safety and pharmacokinetics. Phase 1b: All subjects will take 3 tablets of PCO-02 containing 1 mg of Bepecin every 8 hours during two weeks, to study safety and pharmacokinetics.

NCT07437547RecruitingPh 2BPC-157

BPC 157 for Acute Hamstring Muscle Strain Repair

n=120ClinicalTrials.gov ↗

Start: 2026-02-02Completion: 2028-02-17

Study Interventions

• subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days.

NCT07487363RecruitingPh 1Ph 2TB-500

TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

n=80ClinicalTrials.gov ↗

Start: 2026-02-05Completion: 2028-02-17

Study Interventions

• (thymosin beta 4 17-23 fragment

NCT05932732CompletedPh 4GHK-Cu

Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.

n=27ClinicalTrials.gov ↗

Start: 2023-11-20Completion: 2024-10-09

Study Interventions

• Utilizing patented Vortex Fusion Technology, the HydraFacial Elite MD system cleanses, exfoliates, and hydrates the skin.

• The Regen-GF Booster, a serum formulated to increase collagen and elastin production, will be used during each HydraFacial treatment using the HydraFacial handpiece and specialized tip for application. Ingredients include Heptapeptide-32 maintains the appearance of healthy, youthful skin through collagen and elastin production, Copper Peptide Cu-GHK regenerates healthy-looking skin by accelerating wound healing and skin repair, Palmitoyl Tetrapeptide-7 treats inflammation while boosting the growth of collagen-producing tissues, Palmitoyl Tripeptide-5 helps skin cells flush toxins while enhancing the appearance of firmness, Azelaoyl Bis-Dipeptide 10 addresses signs of aging by managing the formation of free radicals, K3 Vitamin C promotes collagen synthesis, and Hyaluronic Acid hydrates the skin.

• Utilizing patented Vortex Fusion Technology, a pneumatic device, the HydraFacial Syndeo system cleanses, exfoliates, and hydrates the skin.

NCT07437586RecruitingPh 2GHK-Cu

Topical GHK-Cu Gel for Acute Skin Wound Healing

n=60ClinicalTrials.gov ↗

Start: 2026-02-02Completion: 2028-03-17

Study Interventions

• topical gel, 0.1% w/w; apply a thin film (approx. 0.5 g) once daily for 14 days.

NCT02070783CompletedPh 1Ph 2Ara-290

Cognitive and Neural Effects of ARA290

n=36ClinicalTrials.gov ↗

Start: 2012-02Completion: 2014-02

Study Interventions

• ARA290

NCT05230589CompletedSemaglutide

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice

n=194ClinicalTrials.gov ↗

Start: 2022-04-25Completion: 2023-03-13

Study Interventions

• Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.

NCT06745284Active Not RecruitingPh 1Semaglutide

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

n=64ClinicalTrials.gov ↗

Start: 2025-03-26Completion: 2027-01-10

Study Interventions

• Semaglutide

• Survodutide

NCT06363487CompletedNASemaglutide

Semaglutide and Cognition in Healthy Volunteers

n=70ClinicalTrials.gov ↗

Start: 2024-06-06Completion: 2024-12-11

Study Interventions

• Injected subcutaneously (pre-filled pen) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. It is not possible to blind the researcher administering the medication/placebo because semaglutide comes in specific pre-filled pens. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.

NCT05144984CompletedPh 2Semaglutide

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

n=500ClinicalTrials.gov ↗

Start: 2021-11-29Completion: 2023-03-23

Study Interventions

• A weekly dose of semaglutide, same dose in each cohort. The study will last for about 41weeks.

• A weekly dose of NNC0480-0389, dose increased in each cohort. The study will last for about 41weeks.

NCT07204249Not Yet RecruitingPh 2Semaglutide

Glutide for Ending Methamphetamine

n=162ClinicalTrials.gov ↗

Start: 2026-01-15Completion: 2030-02-15

Study Interventions

• Semaglutide

NCT06426446UnknownNASemaglutide

Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data

n=80ClinicalTrials.gov ↗

Start: 2024-06-01Completion: 2025-06-01

Study Interventions

• Withings Body Comp Pro from which the following features will be used: body weight, body composition (fat, muscle and bone mass, cardiovascular health (pulse wave velocity, arterial stiffness, vascular age, standing heart rate), nervous health (electrochemical skin conductance)

NCT07223983RecruitingPh 1Semaglutide

Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

n=10ClinicalTrials.gov ↗

Start: 2026-03-06Completion: 2026-10-31

Study Interventions

• Participants randomized to Semaglutide will be initiated on a 0.25 mg dose (injection) once weekly for 4 weeks (first month) with an escalation to 0.5 mg for the second month, and 1.0 mg in the final month (three months total).

NCT06396416RecruitingPh 4Semaglutide

Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

n=60ClinicalTrials.gov ↗

Start: 2024-09-26Completion: 2026-02

Study Interventions

• Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.

• Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.

NCT06788626Not Yet RecruitingPh 3Semaglutide

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

n=390ClinicalTrials.gov ↗

Start: 2025-02Completion: 2028-02

Study Interventions

• Standard medical management

• 0.5mg semaglutide injection before and 1 week after endovascular treatment.

NCT07244458RecruitingNASemaglutide

Dietary Peanuts and Nutrition-Related Outcomes

n=64ClinicalTrials.gov ↗

Start: 2026-04-20Completion: 2027-12

Study Interventions

• Participants will eat 2 ounces, or about 53 grams, of dry-roasted, lightly salted peanuts each day along with their regular diet

• DEXA scans will be used to measure body fat

NCT06246799RecruitingPh 3Tirzepatide

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

n=256ClinicalTrials.gov ↗

Start: 2024-11-07Completion: 2029-06-30

Study Interventions

• Sitagliptin: will be administered as a 100mg dose once daily.

• Pioglitazone: Participants will begin therapy at 15mg daily for the first 4 weeks then increase dose to 30mg at week 4 and to 45 mg at week 8, as tolerated.

• Tirzepatide:Participants will be initiated on 2.5mg weekly and increase their dose to 5mg at week 4, 10mg at week 8 and 15mg at week 12 as tolerated.

• Metformin will be administered at a dose of 1000mg for the first 4 weeks and then the dose increased to 2000mg.

NCT07244458RecruitingNATirzepatide

Dietary Peanuts and Nutrition-Related Outcomes

n=64ClinicalTrials.gov ↗

Start: 2026-04-20Completion: 2027-12

Study Interventions

• Participants will eat 2 ounces, or about 53 grams, of dry-roasted, lightly salted peanuts each day along with their regular diet

• DEXA scans will be used to measure body fat

NCT07567378Not Yet RecruitingTirzepatide

CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry

n=30ClinicalTrials.gov ↗

Start: 2026-05Completion: 2029-05

Study Interventions

• Dual GLP-1 and GIP receptor agonist administered subcutaneously at doses and intervals determined by the treating physician independently of this registry. The registry does not supply, initiate, modify, or discontinue tirzepatide; exposure is documented from the medical record and patient report.

NCT04081337CompletedPh 1Tirzepatide

A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

n=55ClinicalTrials.gov ↗

Start: 2020-07-09Completion: 2022-05-26

Study Interventions

• Administered SC

NCT06737042Not Yet RecruitingPh 2Tirzepatide

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

n=285ClinicalTrials.gov ↗

Start: 2025-02-12Completion: 2026-06-22

Study Interventions

• Active Comparator

• GLP-1

NCT03131687CompletedPh 2Tirzepatide

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

n=318ClinicalTrials.gov ↗

Start: 2017-05-24Completion: 2018-08-01

Study Interventions

• Administered SC

NCT07088718CompletedTirzepatide

Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

n=44,671ClinicalTrials.gov ↗

Start: 2024-10-01Completion: 2025-07-30

Study Interventions

• New use of tirzepatide dispensing claim is used as the exposure.

• New use of dulaglutide dispensing claim is used as the reference.

NCT06965413Active Not RecruitingPh 2Tirzepatide

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

n=285ClinicalTrials.gov ↗

Start: 2025-05-05Completion: 2027-07-23

Study Interventions

• Tirzepatide will be administered as per the schedule specified in the arms.

• RO7204239 or matching placebo will be administered as per the schedule specified in the arms.

NCT03987919CompletedPh 3Tirzepatide

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

n=1,879ClinicalTrials.gov ↗

Start: 2019-07-30Completion: 2021-02-15

Study Interventions

• Administered SC

NCT04166773CompletedPh 2Tirzepatide

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

n=190ClinicalTrials.gov ↗

Start: 2019-11-19Completion: 2024-01-10

Study Interventions

• Administered SC

NCT06859268Active Not RecruitingPh 3Retatrutide

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

n=643ClinicalTrials.gov ↗

Start: 2025-03-05Completion: 2028-04

Study Interventions

• Administered SC

NCT06808802CompletedPh 1Retatrutide

To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants

n=30ClinicalTrials.gov ↗

Start: 2025-02-03Completion: 2025-04-15

Study Interventions

• Administered orally

• Administered subcutaneously (SC)

NCT07357415RecruitingPh 3Retatrutide

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

n=600ClinicalTrials.gov ↗

Start: 2026-01-24Completion: 2028-11

Study Interventions

• Administered SC

NCT05936151CompletedPh 2Retatrutide

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

n=146ClinicalTrials.gov ↗

Start: 2023-07-20Completion: 2025-10-21

Study Interventions

• Administered SC

NCT07232719Active Not RecruitingPh 3Retatrutide

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

n=250ClinicalTrials.gov ↗

Start: 2025-11-17Completion: 2027-07

Study Interventions

• Administered SC

NCT05882045Active Not RecruitingPh 3Retatrutide

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

n=1,800ClinicalTrials.gov ↗

Start: 2023-05-30Completion: 2026-05

Study Interventions

• Administered SC

NCT05929066Active Not RecruitingPh 3Retatrutide

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

n=2,300ClinicalTrials.gov ↗

Start: 2023-07-10Completion: 2026-05

Study Interventions

• Administered SC

NCT06297603Active Not RecruitingPh 3Retatrutide

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

n=320ClinicalTrials.gov ↗

Start: 2024-03-15Completion: 2026-11

Study Interventions

• Administered SC

NCT06662383Active Not RecruitingPh 3Retatrutide

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

n=800ClinicalTrials.gov ↗

Start: 2024-11-01Completion: 2026-12

Study Interventions

• Administered SC

NCT04143802CompletedPh 1Retatrutide

A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

n=72ClinicalTrials.gov ↗

Start: 2019-12-18Completion: 2020-12-28

Study Interventions

• Administered SC

NCT05767255UnknownPh 3Liraglutide

Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue

n=66ClinicalTrials.gov ↗

Start: 2022-12-01Completion: 2023-08-30

Study Interventions

• The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent and safe drug that reduces the risk of hypoglycemia.

• The insulin dose of the basal group will be adjusted according to the blood glucose reports presented by the patients.

NCT03235050CompletedPh 2Liraglutide

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

n=834ClinicalTrials.gov ↗

Start: 2017-08-02Completion: 2019-06-14

Study Interventions

• Pharmaceutical form: solution Route of administration: subcutaneous

NCT02001363UnknownNALiraglutide

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

n=90ClinicalTrials.gov ↗

Start: 2013-11Completion: 2016-03

Study Interventions

• once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days

NCT02104037CompletedNALiraglutide

Liraglutide in Spinal Fluid

n=8ClinicalTrials.gov ↗

Start: 2012-01

Study Interventions

• Lumbar puncture

NCT02686177CompletedPh 4Liraglutide

Effect of GLP-1 on Angiogenesis

n=50ClinicalTrials.gov ↗

Start: 2016-05-18Completion: 2021-05-28

Study Interventions

• Metformin or sulfonylurea

• Liraglutide

NCT01299012CompletedLiraglutide

Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus

n=30ClinicalTrials.gov ↗

Start: 2010-10Completion: 2013-06

Study Interventions

• Liraglutide s/c 0.6mg once daily.

NCT02109315WithdrawnPh 1Liraglutide

Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.

0ClinicalTrials.gov ↗

Start: 2014-05Completion: 2015-05

Study Interventions

• Liraglutide endovenous de 0.6 mg. one time a day

• C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min

NCT02443155CompletedPh 2Liraglutide

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

n=308ClinicalTrials.gov ↗

Start: 2015-11-10Completion: 2019-02-27

Study Interventions

• NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment

• Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment

NCT01890993CompletedLiraglutide

Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

n=952ClinicalTrials.gov ↗

Start: 2013-08Completion: 2014-06

Study Interventions

• Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.

NCT01722240CompletedPh 3Liraglutide

Liraglutide in Type 1 Diabetes

n=69ClinicalTrials.gov ↗

Start: 2012-11-01Completion: 2019-07-29

Study Interventions

• Liraglutide 1.8mg

NCT04013568CompletedNAMOTS-c

Exercise Post-Diagnosis of Breast Cancer

n=62ClinicalTrials.gov ↗

Start: 2019-08-28Completion: 2026-03-06

Study Interventions

• First Intervention 12-week exercise program, 3 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific. Private or semi-private (1:1 or 2:1 ratio participant to instructor) sessions, led by Kinesiology students Second Intervention- 12-week exercise program, 2 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific. Group Fitness Classes

NCT04027712UnknownMOTS-c

Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD

n=120ClinicalTrials.gov ↗

Start: 2014-01-01Completion: 2021-12-31

NCT03878706RecruitingMOTS-c

The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

n=240ClinicalTrials.gov ↗

Start: 2017-11-03Completion: 2027-06-30

NCT07505745RecruitingPh 2MOTS-c

MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity

n=120ClinicalTrials.gov ↗

Start: 2026-02-02Completion: 2028-05-17

Study Interventions

• Drug: MOTS-c (MDP)

• injection

• Fixed dose once daily for 12 weeks

NCT05076045CompletedNASelank

Effects of PSAPs on Speech Processing

n=32ClinicalTrials.gov ↗

Start: 2022-03-01Completion: 2022-10-01

Study Interventions

• Participants will be tested with bilateral personal sound amplification products.

NCT00464269CompletedPh 3Selank

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

n=400ClinicalTrials.gov ↗

Start: 2007-09Completion: 2009-01

Study Interventions

• * Active Substance: Brivaracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 2.5 mg * Route of Administration: Oral use

• * Active Substance: Brivaracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 10 mg * Route of Administration: Oral use

• * Active Substance: Brivaracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 25 mg * Route of Administration: Oral use

NCT05832060UnknownNASelank

Comparing the Efficacy of tDCS and tRNS to Improve Reading Skills in Children and Adolescents With Dyslexia

n=24ClinicalTrials.gov ↗

Start: 2023-05-01Completion: 2025-03-01

Study Interventions

• Active tDCS will be delivered over TPC for a stimulation session. The anodal electrode will be placed on the left TPC, T7/TP7 position according to the 10-20 International EEG 10-20 System for electrode placement. The cathodal electrode will be placed on the right TPC, T8/TP8 position. Intensity will be set at 1 mA, the duration of stimulation will be 20 min.

• Active tRNS will be delivered to bilateral TPC for a stimulation session. The electrodes will be placed on the left and right TPC, respectively T7/TP7 and T8/TP8 position, at 0.75 mA (100-500 Hz) for 20 min.

• Sham tRNS or tDCS will be delivered over bilateral TPC for a stimulation session. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down without the participants awareness.

NCT04989088UnknownNASelank

Neurofeedback Training for Dyslexia

n=40ClinicalTrials.gov ↗

Start: 2021-10Completion: 2022-06

Study Interventions

• Left theta/beta NF training in combination with right beta/theta NF training in temporo-parietal regions, for 40 minutes (with a 20-minute break period)

• Sham NF training using pre-recorded videos, for 40 minutes (with a 20-minute break period)

NCT05411185CompletedSelank

The Study on Effects of Acute Exposure to High Altitude Hypoxia on Cognitive Function in Lowlanders

n=43ClinicalTrials.gov ↗

Start: 2022-01-01Completion: 2023-12-31

NCT00504881CompletedPh 3Selank

Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy

n=480ClinicalTrials.gov ↗

Start: 2007-10Completion: 2008-12

Study Interventions

• Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period

NCT01770990CompletedNASelank

Trial of Telephone-based Psychotherapy for Depression With and Without Adjunctive Supportive Mail

n=59ClinicalTrials.gov ↗

Start: 2012-09Completion: 2015-04

Study Interventions

• Patients receive telephone-based psychotherapy and one letter after each telephone session.

• Patients receive telephone-based psychotherapy without additional letters.

NCT07196085CompletedNASelank

Neural Mechanisms and Efficacy of Imagery Rescripting for Fear of Failure

n=81ClinicalTrials.gov ↗

Start: 2022-06-01Completion: 2023-05-30

Study Interventions

• Four ImRs sessions over 2 weeks, targeting autobiographical criticism memory. Therapist-guided rescripting involved modifying the "hotspot" scene (critical interaction) with protective interventions addressing unmet needs.

• Four neutral imagery sessions over 2 weeks. Participants imagined neutral interpersonal interactions matched in structure and duration to ImRs but with rescription of neutral instead of criticism memories.

NCT01747200CompletedNASelank

Effects of Transcranial Magnetic Stimulation on Object Recognition

n=13ClinicalTrials.gov ↗

Start: 2012-11-16Completion: 2017-01-26

Study Interventions

• Bilateral rTMSat same frequency and out of phase

• Bilateral rTMS at different frequencies

• Sham rTMS

• rTMS over TP7

• Bilateral rTMS at same frequency and in phase

• rTMS over TP8

NCT06151093CompletedNASelank

The Effect of Balance Exercises on Cognitive Function

n=30ClinicalTrials.gov ↗

Start: 2023-09-08Completion: 2024-06-05

Study Interventions

• 1st-2nd Week Applications On a flat-hard surface; * Standing on 2 legs * Stepping forward and backward (separately for both feet) * Getting into the tandem position and maintaining the position (separately for both feet) * Standing on one leg (separately for both feet) * Weight transfer in four directions * Taking a step back towards the step * Stepping on the stability ball 3rd-4th Week Applications All exercises which applied in 1st and 2nd week are applied on mat. 5th-6th Week Applications On the balance board; * Standing on 2 legs * Stepping forward and backward (separately for both feet) * Getting into the tandem position and maintaining the position (separately for both feet) * Standing on one leg (separately for both feet) * Weight transfer in four directions * Catching balls thrown by the enforcer

• These games are applied via using Nintendo Wii 1st - 2nd Week Applications * Basic Step * Penguin slide (right-left weight transfer) * Snowball flight (right-left weight transfer) * Tilt city (right-left weight transfer) 3rd-4th Week Applications * Advanced Step * Snowball flight (right-left weight transfer) * Penguin slide (right-left weight transfer) * Table tilt (weight transfer in 4 directions) 5th-6th Week Applications * Advanced Step * Table tilt (weight transfer in 4 directions) * Balance bubble (weight transfer to 4 directions) * Ski slalom (weight transfer in 4 directions)

NCT06273020UnknownPh 4Cerebrolysin

Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke

n=60ClinicalTrials.gov ↗

Start: 2022-11-17Completion: 2024-12

Study Interventions

• Blood-brain barrier (BBB) disruption will be measured using dynamic susceptibility contrast (DSC) magnetic resonance imaging. DSC MRI is collected during the injection of a gadolinium bolus and the majority of the change in recorded signal in this T2-weighted sequence is due to intravascular contrast. However, in the setting of gadolinium leakage through the BBB into the brain parenchyma, the recorded signal is altered by a T1 effect. An arrival time correction is performed to account for regional difference in blood flow after which the signal is separated into an intravascular and an extravascular component using a comparison with unaffected tissue.The extravascular component is captured with the metric K2 which reflects the fraction of the recorded signal that is due to gadolinium leakage and is a measure of BBB disruption.

• Cerebrolysin would be prepared according to manufacturer's instructions: 30 mL of cerebrolysin in 100 ml of saline solution every 24 hours to a minimum of 10 days and a maximum of 14 days

NCT07043686RecruitingNACerebrolysin

Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study

n=30ClinicalTrials.gov ↗

Start: 2025-06-13Completion: 2027-10-15

Study Interventions

• The patients will receive Cerebrolysin treatment, 10 days consecutively, 30 ml/day, intravenous infusion diluted up to 100 ml of 0.9% saline in 15 minutes.

• "Standard treatment" entails acute ischemic stroke reperfusion treatment according to international guidelines and local policies, instituting secondary preventive treatment, a proper management of stroke risk factors and neurorehabilitation according to patient's needs: locomotor physiotherapy, occupation therapy, speech therapy, and neuropsychological assessment.

NCT01388738CompletedPh 3Cerebrolysin

Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.

n=30ClinicalTrials.gov ↗

Start: 2011-01Completion: 2011-11

Study Interventions

• Cerebrolysin IV 10 ml daily 10 days

• citicoline IV 2000 mg, then citicoline 900 mg/day (300mg\*3 times per day) per os

• choline alfoscerate IV 1000mg daily 10 days

NCT02116348UnknownPh 2Cerebrolysin

Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral Palsy

n=100ClinicalTrials.gov ↗

Start: 2014-04Completion: 2016-04

Study Interventions

• Cerebrolysin will be given to the intervention group

NCT01787123CompletedPh 2Ph 3Cerebrolysin

Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage

n=50ClinicalTrials.gov ↗

Start: 2013-12-01Completion: 2019-01-01

Study Interventions

• 14-day course of intravenous normal saline started within 4 days of ictus

• 14-day course of intravenous Cerebrolysin started within 4 days of ictus

NCT06677502Enrolling By InvitationNACerebrolysin

Cerebrolysin in Critically Ill Patients With Delirium

n=500ClinicalTrials.gov ↗

Start: 2024-01-01Completion: 2025-12-31

Study Interventions

• Patients were randomized into two groups: CBL - patients treated with cerebrolysin at the daily dose of 50 mL, and K - control patients treated without cerebrolysin. Cerebrolysin was administrated intravenously on the day the delirium was detected and then for seven consecutive days.

• Patients enrolled in group K received the infusion of 0.9% Saline solution at a volume of 250 mL.

NCT01822951WithdrawnPh 4Cerebrolysin

Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)

0ClinicalTrials.gov ↗

Completion: 2016-12

Study Interventions

• Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20. Placebo for donepezil:1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o.

• 5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o. Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.

NCT06897176RecruitingPh 4Cerebrolysin

Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study

n=40ClinicalTrials.gov ↗

Start: 2025-03-12Completion: 2027-12-31

Study Interventions

• This intervention uses Cerebrolysin, which is a treatment aimed at improving language abilities and providing neuroprotection for patients with non-fluent aphasia following a stroke. Cerebrolysin is administered via intravenous injection, with the goal of improving language skills and promoting brain function recovery. The treatment is evaluated based on improvements in language abilities, neurological function recovery, and safety.

NCT06052787CompletedPh 3Cerebrolysin

Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU

n=150ClinicalTrials.gov ↗

Start: 2023-09-01Completion: 2025-08-01

Study Interventions

• The dopaminergic agonist amantadine enhances presynaptic dopamine release and inhibits dopamine reuptake, resulting in an increased amount of dopamine in the synaptic cleft. Amantadine may also increase the density of postsynaptic dopamine receptors and alter the conformation of these receptors. Amantadine acts as an NMDA receptor antagonist, blocking glutamate, an NMDA channel activator. This effect may be responsible for amantadine's possible beneficial effect soon after TBI

• Cerebrolysin, a mixture of free amino acids and low molecular weight peptides, has a neurotrophic factor-like activity with immediate pleiotropic neuroprotective activity and long-term multimodal effects on endogenous post-lesional regulation. Cerebrolysin has been suggested to exert beneficial effects on neurobehavioural functions, cognitive performance , and neuro-motor recovery , as part of initial therapy in severe and moderate acute TBI.

NCT02581371UnknownPh 4Cerebrolysin

Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm

n=30ClinicalTrials.gov ↗

Start: 2015-02Completion: 2017-02

Study Interventions

• Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval

NCT06233331Not Yet RecruitingPh 1P21

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

n=9ClinicalTrials.gov ↗

Start: 2026-06Completion: 2027-12

Study Interventions

• Level 2 will consist of 5% ACU-D1 ointment, used twice daily for 4 weeks.

• ACU-D1 is a topical therapeutic agent that has pentaerythritol tetrakis (3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate) (PTTC) as its major active ingredient. PTTC is a novel proteasome inhibitor that has antiangiogenic and anti-inflammatory activities that reduce pro-inflammatory cytokines. ACU-D1 ointment contains a range of 2.5% to 10% weight by volume of PTTC. Level 1 will consist of 2.5% ACU-D1 ointment, used twice daily for 4 weeks.

• 3 vulvar or perianal biopsies are to be performed at the screening as well as at the end of the study (week 4).

• Level 3 will consist of 10% ACU-D1 ointment, used twice daily for 4 weeks.

NCT06280560RecruitingP21

Impact of IVF Hormonal Therapy on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation

n=60ClinicalTrials.gov ↗

Start: 2024-02-01Completion: 2025-12-30

Study Interventions

• Recruited among women belonging to the oocyte donation program and will follow the procedures described above for the Natural Cycle group. No hormonal stimulation. From day 6 of the menstrual period, follicular growth will be evaluated. As soon as a follicle reaches 17mm in diameter, ovulation test strips will be provided to assess LH levels in the first morning urine. The participant will report the positive and will be scheduled for sampling seven days later. An endometrial biopsy and a blood sample will be obtained 7 days after LH peak (LH+7)

• Short COS protocol with GnRH antagonist followed by progesterone supplementation. Will be initiated after a negative vaginal ultrasonographic scans to define ovarian quiescence, on days 1 and 2 of the menstrual period. For ovarian stimulation, 150-225 UI /day of FSHrec (GONAL F) will be administered along or in combination with 75 UI/day of HMG (Menopur). From day 6 onwards, HMG/FSHrec will be administered on an individual basis according to the serum E2 levels and transvaginal ovarian ultrasound scans and GnRH antagonist (Orgalutran) 0.25 mg /day is introduced as soon as a follicle of 14 mms diameter has achieved. hCGrec (6500 IU, Ovitrelle) will be administered when 7 or 8 follicles with a maximum diameter of \>17-18 mms will observed. 400 mg of micronized vaginal progesterone will be administered (200 mg twice a day vaginal route), during 5 days. An endometrial biopsy and a blood sample will be obtained 7 days after hCG administration (hCH+7)

• No hormonal stimulation. From day 6 of the menstrual period, follicular growth will be evaluated. As soon as a follicle reaches 17mm in diameter, ovulation test strips will be provided to assess LH levels in the first morning urine. The participant will report the positive and will be scheduled for sampling seven days later. An endometrial biopsy and a blood sample will be obtained 7 days after LH peak (LH+7)

• 6 mg of oestradiol orally administered starting the first day of the menstrual period, followed by an endometrial scan 10-days later, and when a 7 mms triple line endometrium has seen by vaginal ultrasound scan, 800 mg of micronized vaginal progesterone (400 mg twice a day vaginal route), during five days, will be added to the oestrogen therapy. An endometrial biopsy and a blood sample will be obtained on day 5 of progesterone administration (P+5)

NCT03818100UnknownP21

Neo-RT: A Study Investigating Whether Changing the Sequence of Treatments (Starting Radiotherapy Followed by Hormone Therapy Before Surgery) is Feasible

n=43ClinicalTrials.gov ↗

Start: 2018-03-26Completion: 2022-12-31

Study Interventions

• Simultaneous integrated boost technique using IMRT: 48 Gray (Gy) and 40 Gy will treat tumour and breast tissue respectively, in 15 fractions over 3 weeks.

• Endocrine therapy will commence following completion of radiotherapy, and will continue for 20 weeks.

• Surgery carried out using local protocol following completion of endocrine therapy.

NCT01342770TerminatedPh 2P21

Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer

n=6ClinicalTrials.gov ↗

Start: 2011-04Completion: 2013-02

Study Interventions

• Correlative studies

• Ancillary studies

• Given PO

NCT03155620Active Not RecruitingPh 2P21

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

n=1,377ClinicalTrials.gov ↗

Start: 2017-07-31Completion: 2027-01-06

Study Interventions

• Correlative studies

• Undergo tumor tissue mutation screening

• Undergo molecular analysis

• Undergo CT, PET/Ct, and/or CT/MRI

• Undergo a bone scan

• Undergo PET, PET/CT, and/or PET/MRI

• Undergo radionuclide imaging

• Undergo blood sample collection

• Given PO

• Given PO or via nasogastric or gastric tube

• Receive PO

• Undergo a bone marrow and/or biopsy

• Undergo biopsy

• Undergo an x-ray

• Undergo MRI, PET/MRI, and/or CT/MRI

• Given PO or via nasogastric- or gastric-tube

NCT04259879CompletedNAP21

Molecular Pathways Related to Short-term Fasting Response

n=20ClinicalTrials.gov ↗

Start: 2016-04-07Completion: 2016-06-15

Study Interventions

• Food intake restriction

NCT03303846Active Not RecruitingNAP21

Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients

n=344ClinicalTrials.gov ↗

Start: 2017-10-13Completion: 2026-11-20

Study Interventions

• Correlative studies

• Undergo blood and tissue sample collection

• Undergo high risk breast cancer screening MRI

NCT05050461TerminatedNAP21

Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma

n=120ClinicalTrials.gov ↗

Start: 2021-11-15Completion: 2023-11-15

Study Interventions

• Immunological analyses will be performed at inclusion in both arms

NCT01860599CompletedNAP21

Effects of Aerobic Exercise in Patients With Pre-diabetes

n=30ClinicalTrials.gov ↗

Start: 2010-03Completion: 2013-05

Study Interventions

• Pre-study activity level (i.e. no exercise)

• 150 minutes of moderate exercise per week

NCT01938716TerminatedNAP21

Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy

n=12ClinicalTrials.gov ↗

Start: 2012-03Completion: 2019-06-03

Study Interventions

• 500 mg/m2 at a fixed dose rate of 10 mg/m2/min by vein for the first 5 patients during pancreatic surgery. Next 15 subsequent patients receive 750 mg/m2 by vein at a fixed dose rate of 10 mg/m2/min.

NCT06125249UnknownHumanin

Humanin's Value for Early Diagnosis and Short-term Prognosis in Patients With AKI After Heart Transplantation

n=60ClinicalTrials.gov ↗

Start: 2022-07-01Completion: 2024-06

NCT06105229UnknownHumanin

Clinical Value of Plasma Humanin in Acute Kidney Injury

n=60ClinicalTrials.gov ↗

Start: 2022-08-01Completion: 2024-06

NCT03431844CompletedHumanin

Humanin Isoforms in Cardiac Muscle and Blood Plasma and Major Complications After Cardiac Operation

n=106ClinicalTrials.gov ↗

Start: 2018-01-01Completion: 2019-08-31

NCT05506228RecruitingHumanin

How Are the Muscles Affected in Cerebral Palsy? A Study of Muscle Biopsies Taken During Orthopaedic Surgery.

n=150ClinicalTrials.gov ↗

Start: 2002-01-15Completion: 2033-12-15

Study Interventions

• No intervention

NCT04104958UnknownHumanin

IVF Outcome in Polycystic Ovary Syndrome Patients

n=100ClinicalTrials.gov ↗

Start: 2020-03-01Completion: 2021-02-15

Study Interventions

• RNA extraction and RT-qPCR Protein extraction and western blotting ELISA assay

NCT07438002RecruitingNAHumanin

Analysis of Effects of High-intensity Physical Exercise in Subjects With Dialyzed Chronic Kidney Disease and in Conservative Treatment

n=50ClinicalTrials.gov ↗

Start: 2025-09-02Completion: 2026-09

Study Interventions

• outcome measures

• All participants will be involved in the exercise training three times per week for 24 weeks: endurance exercise training, resistant exercise training

NCT05168774CompletedPh 1Ph 2SS-31

FRDA Investigator Initiated Study (IIS) With Elamipretide

n=20ClinicalTrials.gov ↗

Start: 2022-03-03Completion: 2024-07-25

Study Interventions

• Elamipretide is a tetra peptide with limited blood brain barrier penetration being developed for use in a variety of mitochondrial disorders, including FRDA, mitochondrial myopathy and Barth Syndrome.

NCT01229579CompletedNAThymulin

Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in Pakistan

n=320ClinicalTrials.gov ↗

Start: 2010-05Completion: 2011-01

Study Interventions

• 2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc from day 14 to 18 weeks of age.

NCT02366247UnknownPh 3Thymosin Alpha-1

Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B

n=463ClinicalTrials.gov ↗

Start: 2013-08Completion: 2016-02

Study Interventions

• 3.2mg/ml, once a week, taken subcutaneously

• 10 mg, once daily, taken orally for 48 weeks

NCT03082885CompletedNAThymosin Alpha-1

The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF

n=120ClinicalTrials.gov ↗

Start: 2017-04-10Completion: 2019-07-30

Study Interventions

• 1.6 mg s.c injection once per day for 7 days, then 1.6 mg s.c injection twice a week for 11 weeks.

NCT00291616CompletedPh 4Thymosin Alpha-1

Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B

n=52ClinicalTrials.gov ↗

Start: 2005-12Completion: 2008-08

Study Interventions

• 180 microgram s.c. injection weekly

• Pegylated interferon 180 microgram s.c. injection weekly Thymosin 1.6 mg s.c. injection twice per week

NCT02787447UnknownPh 2Thymosin Alpha-1

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

n=46ClinicalTrials.gov ↗

Start: 2016-05Completion: 2020-05

Study Interventions

• Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid

• Initiating thymosin alpha 1 therapy(1.6mg, qd, d1-d14;1.6mg, biw, d15-d90) at the second week of radiotherapy.

• 40-45 Gy/5-15f

NCT02535988WithdrawnPh 2Thymosin Alpha-1

Abscopal Effect for Metastatic Colorectal Cancer

0ClinicalTrials.gov ↗

Start: 2015-09Completion: 2017-12

Study Interventions

• Patients with metastatic lesions of colorectal cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).

• 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of colorectal cancer.

NCT07103408Not Yet RecruitingPh 2Thymosin Alpha-1

A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer

n=56ClinicalTrials.gov ↗

Start: 2025-10-01Completion: 2029-09-30

Study Interventions

• Immuno-chemotherapy regimen included etoposide, cisplatin, iparomlimab and tuvonralimab, and thymosin alpha 1.

• Consolidation therapy regimen included iparomlimab and tuvonralimab, and thymosin alpha 1, with a duration of one year.

• Definitive dose of thoracic radiotherapy was delivered no later than the three cycle of immuno-chemotherapy. Prophylactic cranial irradiation (PCI) was delivered with a total dose of 25Gy in 10 fractions. PCI was recommended for patients who achieved complete response or partial response after thoracic chemoradiotherapy.

NCT04963712CompletedEARLY_Ph 1Thymosin Alpha-1

Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder

n=20ClinicalTrials.gov ↗

Start: 2021-09-01Completion: 2022-08-11

Study Interventions

• 1.6 mg subcutaneous injection, once a day in the first 2 weeks, and 1.6 mg subcutaneous injection, twice a week in the successive 22 weeks.

NCT04524169UnknownPh 4Thymosin Alpha-1

Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain

n=100ClinicalTrials.gov ↗

Start: 2020-11-01Completion: 2021-12-31

Study Interventions

• Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.

NCT02906150UnknownPh 2Thymosin Alpha-1

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

n=140ClinicalTrials.gov ↗

Start: 2016-09Completion: 2019-07

Study Interventions

• Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.

• Patients will be randomized to Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.

NCT01943617CompletedPh 4Thymosin Alpha-1

Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis

n=606ClinicalTrials.gov ↗

Start: 2013-06Completion: 2016-12

Study Interventions

• anti-viral and antitherapy

• anti-viral therapy

NCT03271489CompletedPh 3VIP

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

n=478ClinicalTrials.gov ↗

Start: 2017-09-13Completion: 2024-06-28

Study Interventions

• Estradiol 1 mg/norethindrone acetate 0.5 mg capsules

• Film-coated 300 mg tablets

NCT01704690TerminatedPh 2Ph 3VIP

Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer

n=4ClinicalTrials.gov ↗

Start: 2012-08Completion: 2017-03

Study Interventions

• The cisplatin and 5-fluorouracil combination will be used in the Cisplatin and 5-FU arm.

• S-1 and Paclitaxel are used in the S-1 and Paclitaxel arm.

• The paclitaxel and cisplatin combination will be used in the Paclitaxel and Cisplatin arm.

NCT06426316RecruitingNAVIP

The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.

n=396ClinicalTrials.gov ↗

Start: 2025-06-02Completion: 2027-04-30

Study Interventions

• 1 blood test of maximum 40 millilitres per patient

NCT05144984CompletedPh 2VIP

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

n=500ClinicalTrials.gov ↗

Start: 2021-11-29Completion: 2023-03-23

Study Interventions

• A weekly dose of semaglutide, same dose in each cohort. The study will last for about 41weeks.

• A weekly dose of NNC0480-0389, dose increased in each cohort. The study will last for about 41weeks.

NCT04822506UnknownNAVIP

PEA Promote Gastrointestinal Function Recovered After Colorectal Cancer Operation

n=30ClinicalTrials.gov ↗

Start: 2021-07-31Completion: 2023-10-31

Study Interventions

• Routine perioperative management： All patients were given perioperative fluid rehydration and nutritional support to correct acid-base imbalance, electrolyte disturbance, anti-infection, hemostasis and other symptomatic treatment； electroacupuncture protocol： Preoperation:RN 6 + RN 4 +ST30 + ST 36+ Hegu (bilateral),De qi, electroacupuncture, continuous wave, 5Hz, 30min before surgery at 19:00 PM Inoperatively: LI 4+ PC 6 + ST36 + GB 34 (bilateral) ,Deqi, electroacupuncture with density wave, 2/100Hz, 30 minutes before operation to the end of the operation Postoperative: LI 4 +SJ 6 + ST 6 + ST 37(Left);LI 4 +SJ 6 + ST 6 + ST 37(Right)(alternated on both sides per 12h) Deqi, electroacupuncture, continuous wave, 5Hz, 30min,19:00 on the left side and 07:00 on the next day after surgery,until to first flatus (FF)

NCT06796062RecruitingPh 2VIP

Psilocybin for Opioid Use Disorder (OUD)

n=480ClinicalTrials.gov ↗

Start: 2025-12-17Completion: 2029-02

Study Interventions

• One capsule (1 mg, 20 mg, or 30 mg) administered once orally

NCT00312806CompletedPh 3VIP

Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)

n=2,000ClinicalTrials.gov ↗

Start: 2006-05Completion: 2007-07

Study Interventions

• Pantoprazole 40 mg o.d.

NCT00212576CompletedNAVIP

Promoting Early School Readiness in Primary Health Care

n=675ClinicalTrials.gov ↗

Start: 2005-11Completion: 2017-12-18

Study Interventions

• This project employs a public health approach to facilitate parental engagement in child development. Families are sent monthly newsletters that focus on child development, infant cues and parenting; included with each newsletter is an inexpensive, developmentally stimulating toy. In addition, families periodically receive Ages and Stages Questionnaires, which they complete and mail back to the program. Based on the questionnaires, the program determines whether the infant has screened positive for possible developmental delay and provides this information to both the family and the primary care provider.

• While waiting to see the primary care provider for well child care, the family meets with a child development specialist, who videotapes the parent and infant interacting together. The videotape is then rewound and watched together by the parent and child development specialist. This leads to a discussion about child development, infant cues and parenting, with the child development specialist building on observed strengths in the interaction. In addition, families are provided with parenting pamphlets developed for the project, and with inexpensive developmentally stimulating toys.

NCT04976309CompletedPh 1VIP

A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects

n=25ClinicalTrials.gov ↗

Start: 2021-07-15Completion: 2021-12-10

Study Interventions

• Single dose

NCT03724656UnknownNAVIP

Effects of Intraoperative Stimulation of Acupoints on Postoperative Gastrointestinal Motility Recovery

n=600ClinicalTrials.gov ↗

Start: 2019-03Completion: 2021-11

Study Interventions

• TAES treatment 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After "Deqi", electroacupuncture stimulation apparatus is connected and maintained until the end of operation.

• Participants in the sham acupuncture group received shallow needling (0.30mm×25mm) at bilateral sham points(nonacupoints located 5cm beside acupoints, about 20mm). The control group was treated with non-acupoint shallow acupuncture method and the needling depth was less than 2 mm. At the same time, the manual stimulation and "Deqi" was avoided.

NCT02178488CompletedPh 2LL-37

Efficacy Study of Vitamin D Supplementation to Meticillin Resistant Staphylococcus Aureus (MRSA) Carriers

n=60ClinicalTrials.gov ↗

Start: 2014-12Completion: 2017-12

Study Interventions

• Cholecalciferol 4000 IU/day for 12 months

NCT02806414CompletedPh 1Ph 2LL-37

Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.

n=25ClinicalTrials.gov ↗

Start: 2016-07Completion: 2021-05

Study Interventions

• Ivermectin

NCT02138591WithdrawnPh 3LL-37

Therapeutic Benefit of Preoperative Supplemental Vitamin D in Patients Undergoing Major Surgical Procedures.

0ClinicalTrials.gov ↗

Start: 2016-02Completion: 2016-05

Study Interventions

• Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.

• Pre-Operative blood draw of approximately 32ml will check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.

NCT01758081Active Not RecruitingNALL-37

Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)

n=25,874ClinicalTrials.gov ↗

Start: 2010-07Completion: 2026-12

Study Interventions

• Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])

• Vitamin D3 (cholecalciferol), 2000 IU per day

NCT01372995CompletedPh 2LL-37

Vitamin D in Ventilated ICU Patients

n=31ClinicalTrials.gov ↗

Start: 2011-07Completion: 2014-04

Study Interventions

• Enteral Vitamin D3 50,000IU x 5 days (total dose 250,000IU)

• Enteral Vitamin D3 100,000IU over 5 days (total 500,000IU)

• Inactive substance given enterally for 5 days.

NCT05244018CompletedPh 4LL-37

Outcome of High Dose Vitamin D on Prognosis of Sepsis Requiring Mechanical Ventilation

n=80ClinicalTrials.gov ↗

Start: 2022-03-01Completion: 2022-10-31

Study Interventions

• Vitamin D tablets 5000 units as daily requirements

• Vitamin D3 tablets 50,000 IU units

NCT01398280CompletedEARLY_Ph 1LL-37

Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation

n=15ClinicalTrials.gov ↗

Start: 2011-07Completion: 2012-12

Study Interventions

• Vehicle cream moisturizer twice daily for up to 12 weeks

• 25% Aminocaproic acid cream twice daily for up to 12 weeks.

NCT06867250CompletedLL-37

Peri-implant Vitamin D and Cathelicidin (LL-37) Levels

n=33ClinicalTrials.gov ↗

Start: 2021-04-01Completion: 2021-12-01

Study Interventions

• In vitro studies have shown that vitamin D promotes the release of antimicrobial peptides from gingival epithelial cells, no clinical research has specifically examined its effect on LL-37 levels in peri-implant tissue diseases. This study seeks to investigate the relationship between vitamin D levels in peri-implant sulcus fluid and clinical parameters in individuals with both peri-implant health and disease. Additionally, it aims to assess the correlation between vitamin D and the antimicrobial peptide LL-37.

NCT04858217RecruitingLL-37

Periprosthetic Joint Infections: Diagnostic Accuracy and Cost-effectiveness Analysis of Serum and Synovial Markers

n=270ClinicalTrials.gov ↗

Start: 2022-02-01Completion: 2026-03-31

NCT01580007CompletedPh 2LL-37

Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)

n=288ClinicalTrials.gov ↗

Start: 2010-12Completion: 2014-12

Study Interventions

• Sodium Phenylbutyrate: 500 mg twice daily orally for 2 months Cholecalciferol: 5000 IU once daily orally for 2 months

NCT07437560RecruitingPh 2Melanotan II

Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo

n=60ClinicalTrials.gov ↗

Start: 2026-02-02Completion: 2028-02-17

Study Interventions

• administered per protocol

• standardized schedule per site protocol

NCT02333071CompletedPh 3PT-141

1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

n=723ClinicalTrials.gov ↗

Start: 2014-12Completion: 2017-06-30

Study Interventions

• A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)

NCT02338960CompletedPh 3PT-141

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

n=714ClinicalTrials.gov ↗

Start: 2015-01Completion: 2017-06-29

Study Interventions

• A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)

NCT01382719CompletedPh 2PT-141

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

n=612ClinicalTrials.gov ↗

Start: 2011-06Completion: 2012-09

Study Interventions

• Subjects will administer drug on an as needed basis, prior to anticipated sexual activity. Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen. Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.

NCT00425256CompletedPh 2PT-141

Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

ClinicalTrials.gov ↗

Start: 2006-02Completion: 2007-05

Study Interventions

• Bremelanotide

NCT05032326UnknownPh 3DES(1-3) IGF-1

Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial

n=80ClinicalTrials.gov ↗

Start: 2021-09-07Completion: 2025-04-01

Study Interventions

• follow-up study of the patients in the treated cohort: that have been included in the otbb3 study

• follow-up study of the patients in the untreated cohort: that have NOT been included in the otbb3 study

NCT00163189CompletedPh 3DES(1-3) IGF-1

Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm

n=98ClinicalTrials.gov ↗

Start: 2005-01Completion: 2014-12

Study Interventions

• Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day

NCT01431625UnknownPh 4DES(1-3) IGF-1

Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype

n=30ClinicalTrials.gov ↗

Start: 2011-01Completion: 2012-12

Study Interventions

• All patients underwent a training program to be held for 12 weeks in sessions of 60 minutes: 1. .- 20 minutes of bicycle ergometer with an initial load level of about 70% of baseline peak oxygen consumption, increasing the load every two weeks as tolerated. 2. \- Weightlifting in 2 sets of 6 reps of 5 simple exercises. These are held at a station multigimnastyc (CLASSIC Fitness Center, KETTLER) and are as follows: "pulls Chest," "Shoulder press," "Butterfly," "Leg extension" and "Leg curls." The resistance will be increased gradually from 70% of the maximum weight you can lift the patient in a single maneuver (Test 1RM). Every two weeks the maximum weight is re-evaluated to adjust the training load in each patient.

NCT05028959UnknownNADES(1-3) IGF-1

Hormonal Status, Performance and Health in Elite Female Athlete

n=80ClinicalTrials.gov ↗

Start: 2021-09-15Completion: 2025-05-31

Study Interventions

• Multidisciplinary monitoring

NCT05163314TerminatedPh 3DES(1-3) IGF-1

A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

n=352ClinicalTrials.gov ↗

Start: 2022-03-04Completion: 2025-09-24

Study Interventions

• Soticlestat mini-tablets or tablets

NCT02616562CompletedPh 2DES(1-3) IGF-1

Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

n=76ClinicalTrials.gov ↗

Start: 2016-03-31Completion: 2024-09-26

Study Interventions

• Administered subcutaneously (s.c., under the skin) once daily.

• Administered subcutaneously (s.c., under the skin) once-weekly.

NCT00516698CompletedDES(1-3) IGF-1

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

n=140ClinicalTrials.gov ↗

Start: 2007-09Completion: 2009-12

Study Interventions

• polymorphism analysis

• high performance liquid chromatography

• laboratory biomarker analysis

• radiomammography

NCT04530214UnknownDES(1-3) IGF-1

Predictive Elements of Trauma and Its After-effects: Importance of the Quality of Neurobiological Response to Stress

n=130ClinicalTrials.gov ↗

Start: 2020-11-04Completion: 2023-05

Study Interventions

• Saliva collection at enrollment (before surgery) and at Visit 1 (45-60 days following surgery)

• Mental health assessment through questionnaires at enrollment (24-72h following surgery), at Visit 1 (45-60 days following surgery), at Visit 2 (7 months following surgery) and at Visit 3 (12 months following surgery)

• Electrocardiography (ECG) at enrollment (24-72h following surgery) and at Visit 1 (45-60 days following surgery) to assess heart rate variability

• Blood collection at enrollment (before surgery) and at Visit 1 (45-60 days following surgery)

NCT03811535CompletedPh 3DES(1-3) IGF-1

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

n=200ClinicalTrials.gov ↗

Start: 2019-05-20Completion: 2025-09-30

Study Interventions

• Somapacitan will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.

• Norditropin® will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.

NCT04015141RecruitingPh 2DES(1-3) IGF-1

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

n=100ClinicalTrials.gov ↗

Start: 2019-05-31Completion: 2027-12-23

Study Interventions

• Perampanel oral suspension.

• Perampanel tablet.

NCT01034202CompletedPh 1PEG-MGF

Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®

n=56ClinicalTrials.gov ↗

Start: 2007-08Completion: 2008-01

Study Interventions

• One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)

• One of two dose levels, followed by placebo, administered subcutaneously (under the skin)

• One of five dose levels administered subcutaneously (under the skin)

• One of three dose levels administered subcutaneously (under the skin)

NCT02375620Active Not RecruitingPh 2PEG-MGF

Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature

n=96ClinicalTrials.gov ↗

Start: 2015-04-23Completion: 2025-12

Study Interventions

• PEG-somatropin

NCT03189160UnknownPh 2PEG-MGF

A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome

n=180ClinicalTrials.gov ↗

Start: 2016-03

Study Interventions

• PEG-rhGH Injection 0.2 mg/kg/w by subcutaneous injection for 52 weeks.

• Non-treatment control group

• PEG-rhGH Injection 0.1 mg/kg/w by subcutaneous injection for 52 weeks.

NCT05456854WithdrawnPh 1Kisspeptin-10

Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp

0ClinicalTrials.gov ↗

Start: 2022-06-03Completion: 2024-08-01

Study Interventions

• Administration of a hyperglycemic clamp

• Administration of kisspeptin-10 \* 16 hr

NCT03771326CompletedPh 3Kisspeptin-10

KP-10 and Insulin Secretion in Men

n=14ClinicalTrials.gov ↗

Start: 2013-10-29Completion: 2014-01-10

Study Interventions

• Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)

NCT03286517CompletedPh 3Kisspeptin-10

Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys.

n=30ClinicalTrials.gov ↗

Start: 2014-06-26Completion: 2015-03-05

Study Interventions

• A neurohormone

NCT04532801WithdrawnPh 1Kisspeptin-10

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance

0ClinicalTrials.gov ↗

Start: 2019-09-01Completion: 2024-12-21

Study Interventions

• mixed meal tolerance test

• kisspeptin-10 IV infusion

NCT03315325CompletedPh 3Kisspeptin-10

Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in Men

n=15ClinicalTrials.gov ↗

Start: 2014-08-08Completion: 2015-03-05

Study Interventions

• Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) is a potent HPG-axis stimulator and control reproduction.

NCT01809691CompletedPh 3Gonadorelin

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

n=1,313ClinicalTrials.gov ↗

Start: 2013-03-08Completion: 2025-09-09

Study Interventions

• 300 mg, PO, twice daily

• 50 mg, PO, q daily

NCT00898326CompletedGonadorelin

PSA Levels and Biopsy Samples After Implant Radiation and Hormone Therapy in Patients With Stage I or Stage II Prostate Cancer

n=198ClinicalTrials.gov ↗

Start: 2011-04-01Completion: 2016-12-31

Study Interventions

• Conduct prostatic needle biopsy at 36-39 months-after brachy therapy. Basic method is by transectal ultra-sound-guided systematic biopsy,; systematic sextant biopsy which involves samples from both seminal vesicles is adopted as much as possible.

NCT00805935CompletedPh 4Gonadorelin

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

n=110ClinicalTrials.gov ↗

Start: 2009-01Completion: 2010-09

Study Interventions

• 100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.

• 50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.

• Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.

• 225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.

NCT00866008TerminatedPh 4Gonadorelin

A Study of the Effects of a Novel Ovarian Stimulation Regimen on Embryo Aneuploidy Rates in In Vitro Fertilization (IVF)

n=34ClinicalTrials.gov ↗

Start: 2008-10Completion: 2011-01

Study Interventions

• 1. Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment 2. Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.

NCT01428089UnknownPh 1Gonadorelin

Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone

n=40ClinicalTrials.gov ↗

Start: 2011-03-11Completion: 2024-12

Study Interventions

• Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml) or placebo at 1100, 1500, and 1900 h.

NCT04071574CompletedPh 1Ph 2Gonadorelin

Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility

n=200ClinicalTrials.gov ↗

Start: 2018-02-01Completion: 2023-05-05

Study Interventions

• Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)

• Administration of hCG (10.000IU) for ovulation triggering

• Administration of Triptorelin (0.1mg/day)

• Administration of cetrorelix (cetrotide) or ganirelix (orgulatron) (0.25mg/day)

NCT03209518CompletedGonadorelin

Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"

n=312ClinicalTrials.gov ↗

Start: 2016-03-18Completion: 2018-10-10

Study Interventions

• Leuplin PRO for Injection Kit 22.5 mg

NCT04189900CompletedPh 1Gonadorelin

Generation of Biological Samples Positive to Triptorelin for Anti-doping Control

n=2ClinicalTrials.gov ↗

Start: 2019-04-26Completion: 2019-05-15

Study Interventions

• Subjects receive a single subcutaneous dose of 0,1 mg of Triptorelin acetate.

NCT01715129CompletedPh 3Gonadorelin

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

n=126ClinicalTrials.gov ↗

Start: 2013-01Completion: 2013-10

Study Interventions

• Triptorelin Pamoate 11.25mg

NCT04891731UnknownGonadorelin

Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer

n=120ClinicalTrials.gov ↗

Start: 2021-05Completion: 2023-09

Study Interventions

• This is an observational study, the researcher will describe the ratio of E2 control between leuprorelin plus TAM or leuprorelin plus AIs patients based on the actual clinical use.

NCT06867835CompletedPh 4Bremelanotide

Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk

n=10ClinicalTrials.gov ↗

Start: 2025-07-11Completion: 2025-11-15

Study Interventions

• Single dose of BMT 1.75 mg SC on Day 1

NCT06565611Active Not RecruitingPh 2Bremelanotide

A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

n=108ClinicalTrials.gov ↗

Start: 2024-08-05Completion: 2025-03-31

Study Interventions

• bremelanotide (BMT) sterile aqueous solution for subcutaneous injection, provided as autoinjectors containing 0.3 mL volume

• tirzepatide (GLP-1/GIP) will be provided in its commercial form for SC injection.

NCT02333071CompletedPh 3Bremelanotide

1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

n=723ClinicalTrials.gov ↗

Start: 2014-12Completion: 2017-06-30

Study Interventions

• A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)

NCT05709444CompletedPh 2Bremelanotide

A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

n=16ClinicalTrials.gov ↗

Start: 2022-12-26Completion: 2024-04-26

Study Interventions

• Bremelanotide is a cyclic, heptapeptide analog of the endogenous peptide alpha melanocortin stimulating hormone (αMSH).

• RAS-acting agents are medicines acting on a hormone system that helps to control blood pressure and the amount of fluid in the body.

NCT03973047CompletedPh 1Bremelanotide

Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

n=228ClinicalTrials.gov ↗

Start: 2019-06-17Completion: 2019-07-20

Study Interventions

• Sterile aqueous solution for injection, provided as an autoinjector pen

• 8 mg tablet (over-encapsulation in a capsule)

NCT02338960CompletedPh 3Bremelanotide

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

n=714ClinicalTrials.gov ↗

Start: 2015-01Completion: 2017-06-29

Study Interventions

• A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)

NCT01382719CompletedPh 2Bremelanotide

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

n=612ClinicalTrials.gov ↗

Start: 2011-06Completion: 2012-09

Study Interventions

NCT04179734CompletedPh 4Bremelanotide

Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder

n=40ClinicalTrials.gov ↗

Start: 2019-10-07Completion: 2020-10-06

Study Interventions

• Melanocortin-4 receptor agonist subcutaneous injection.

NCT04943068CompletedPh 3Bremelanotide

A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

n=193ClinicalTrials.gov ↗

Start: 2021-05-10Completion: 2023-05-16

Study Interventions

• Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.

NCT00425256CompletedPh 2Bremelanotide

Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

ClinicalTrials.gov ↗

Start: 2006-02Completion: 2007-05

Study Interventions

• Bremelanotide

NCT01081249CompletedPh 4Oxytocin

Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting

n=18ClinicalTrials.gov ↗

Start: 2008-12Completion: 2012-07

NCT04727125CompletedOxytocin

Evaluating the Effects of Kangaroo Care in the NICU

n=75ClinicalTrials.gov ↗

Start: 2019-05-17Completion: 2022-01-01

NCT03398278CompletedPh 1Oxytocin

OTR Tablet 40 mg Fasted-state Bioequivalence Study

n=38ClinicalTrials.gov ↗

Start: 2017-06-30Completion: 2018-03-20

Study Interventions

• Orally taking Oxycodone Tamper Resistant 40mg in fast state

• Orally taking OXYCONTIN® 40mg in fast state

NCT06757517RecruitingPh 2Oxytocin

Effects of Intranasal Oxytocin in the Treatment of Benzodiazepine Withdrawal: A Pilot RCT

n=60ClinicalTrials.gov ↗

Start: 2022-03-01Completion: 2025-12-31

Study Interventions

• Syntocinon contains synthetic oxytocinfor intranasal use, 6.7 microg (4 IU) per dose. We are planning to use 4 insufflations (16 IU) three times daily (i.e. a total daily dose of 48 IU).

NCT02564068CompletedEARLY_Ph 1Oxytocin

Oxytocin on HR in Sleep Apnea Patient

n=8ClinicalTrials.gov ↗

Start: 2015-05-22Completion: 2016-12-31

Study Interventions

• To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. 8 subjects that have recently undergone a standard "in the sleep-lab" diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment.

NCT04056793CompletedNAOxytocin

Acceptability Assessment of an Optimized Birthing Position

n=20ClinicalTrials.gov ↗

Start: 2019-08-06Completion: 2020-01-01

Study Interventions

• The parturients will be asked to adopt a supine position with a hyperflexion of the thighs and a flat back, and to maintain the position for a duration of twenty minutes.

NCT01394471CompletedPh 1Oxytocin

Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia

n=68ClinicalTrials.gov ↗

Start: 2011-07Completion: 2015-01

Study Interventions

• 6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks

NCT05444738UnknownNAOxytocin

Effects of Oxytocin Administered Orally Using a Medicated Lollipop on Peripheral Concentrations and Attention

n=72ClinicalTrials.gov ↗

Start: 2022-04-01Completion: 2022-08-30

Study Interventions

• Immediately before drug administration, a blood sample (5ml) is collected. For drug administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after drug administration.

NCT06364228RecruitingPh 2Oxytocin

Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia

n=32ClinicalTrials.gov ↗

Start: 2026-06-20Completion: 2027-06

Study Interventions

• Functional MRI (fMRI) scan with affective Stroop and Empathy and Theory of Mind task (EmpaTom task will administered pre- and post-administration of oxytocin.

• Participants weighing less than 40 kg (88 pounds) will receive 12 IU of oxytocin delivered as 1 puff (6 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (Visit 1).

• Participants weighing more than 40 kg (880 pounds) will receive 24 IU of oxytocin delivered as 2 puffs (12 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (Visit 1).

NCT00385229CompletedNAOxytocin

Post Term Pregnancy - Induction of Labor or Monitoring of Pregnancy

n=508ClinicalTrials.gov ↗

Start: 2002-09Completion: 2004-07

Study Interventions

• Misoprostol, Dinoprostone, amniotomy, Oxytocin

NCT03665350TerminatedPh 2Glucagon

Insulin Treatment in Diabetic Older People With Heart Failure.

n=10ClinicalTrials.gov ↗

Start: 2018-11-08Completion: 2019-09-18

Study Interventions

• Insulin as well as oral anti-diabetic drugs will be prescribed by the responsible physician and/or the diabetologist from each participating site, in conformity with the current guidelines, and the therapeutic target chosen according to patient characteristics. The choice of anti-diabetic medications should be guided by medical needs of each patient and taking into consideration their general safety profile.

NCT07366710Active Not RecruitingNAGlucagon

Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET

n=36ClinicalTrials.gov ↗

Start: 2024-11-05Completion: 2027-10

Study Interventions

• Standard oral glucose load (75 g in 250 mL water) to assess glucose-stimulated metabolic responses during PET/CT.

• Continuous intravenous somatostatin infusion to suppress endogenous pancreatic hormone secretion during the pancreatic clamp.

• Intravenous bolus administration of 18F-fluorodeoxyglucose (18F-FDG) for total-body PET/CT to measure systemic biodistribution and whole-body glucose metabolism.

• Oral administration of O-(2-\[18F\]fluoroethyl)-L-tyrosine (18F-FET) for total-body PET/CT to assess gastrointestinal amino acid absorption and whole-body amino acid metabolism.

• Oral administration of 18F-fluorodeoxyglucose (\^18F-FDG) for total-body PET/CT to assess gastrointestinal absorption, systemic biodistribution, and whole-body glucose metabolism.

• Continuous intravenous glucagon infusion to stimulate hepatic amino acid metabolism during a pancreatic clamp.

• Intravenous bolus administration of O-(2-\[18F\]fluoroethyl)-L-tyrosine (18F-FET) for total-body PET/CT to measure systemic amino acid biodistribution and dynamic metabolic kinetics.

NCT02036710CompletedGlucagon

Location of GLP-1 Release

n=12ClinicalTrials.gov ↗

Start: 2011-11Completion: 2013-10

NCT04372550UnknownNAGlucagon

Effects of Early Exercise Rehabilitation in Severe Burns

n=90ClinicalTrials.gov ↗

Start: 2019-11-25Completion: 2021-10

Study Interventions

• Standard of care rehabilitation

• Resistance and aerobic exercise in addition to standard of care rehabilitation

NCT01337440UnknownPh 4Glucagon

Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases

n=20ClinicalTrials.gov ↗

Start: 2010-04Completion: 2013-03

Study Interventions

• UDCA for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks. UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid.

• Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks. UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid.

NCT03235050CompletedPh 2Glucagon

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

n=834ClinicalTrials.gov ↗

Start: 2017-08-02Completion: 2019-06-14

Study Interventions

• Pharmaceutical form: solution Route of administration: subcutaneous

NCT03713190CompletedPh 2Glucagon

Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).

n=25ClinicalTrials.gov ↗

Start: 2018-09-10Completion: 2020-03-15

Study Interventions

• Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.

NCT07268508RecruitingNAGlucagon

Impact of a Pro-diversity Gut Microbiota Diet After a Bariatric Surgery on Gut Microbiota, Eating Behaviour and Sensory Function

n=60ClinicalTrials.gov ↗

Start: 2025-11-05Completion: 2029-04-05

Study Interventions

• Nutritional counseling

NCT02811276CompletedNAGlucagon

The Impact of a High Protein Diet on Substrate Oxidation and Energy Metabolism

n=20ClinicalTrials.gov ↗

Start: 2016-10Completion: 2018-03

Study Interventions

• The High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®) for one and a half day. Participants will consume 1 gram ± 0.1 of Almased® per kg of body weight mixed with linseed oil and skim milk in their breakfast, lunch and dinner. Two snacks (afternoon and evening) composed of 1 gram ± 0.1 of Almased® per kg of body weight mixed with vegetable juice and linseed oil will also be provided.

NCT02001363UnknownNAGlucagon

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

n=90ClinicalTrials.gov ↗

Start: 2013-11Completion: 2016-03

Study Interventions

NCT06026553UnknownPh 1HCG

Assessing Ketorolac (Toradol) at Oocyte Retrieval

n=400ClinicalTrials.gov ↗

Start: 2022-08-10Completion: 2025-01

Study Interventions

• IV Ketorolac (Toradol) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.

NCT01297465CompletedPh 3HCG

PERgoveriS In Stratified Treatment for Assisted Reproductive Technique

n=202ClinicalTrials.gov ↗

Start: 2011-05-31Completion: 2012-10-31

Study Interventions

• Gonal-f® (follitropin alfa) 300 International Unit (IU) will be administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5).

• Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.

• Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.

• 250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles \>= 18 mm).

NCT00697255TerminatedPh 2HCG

A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)

n=8ClinicalTrials.gov ↗

Start: 2007-05-15Completion: 2008-05-15

Study Interventions

• Daily injections of SC hCG (200 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.

• Daily injections of SC recFSH (50 IU/75 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.

• Bolus injection of SC hCG was administered to induce final oocyte maturation if at least one follicle is ≥18 mm and no more than two follicles ≥15 mm are observed.

• SC corifollitropin alfa on the 1st, 2nd or 3rd day after onset of a progestagen-induced withdrawal bleeding (Stage 1a: 15mcg, Stage Ib/II: 30 mcg).

NCT07394426Not Yet RecruitingEARLY_Ph 1HCG

A Phase I Study of PepGNP-ChikV in Healthy Volunteers

n=40ClinicalTrials.gov ↗

Start: 2026-08-03Completion: 2028-05-01

Study Interventions

• PepGNP-ChikV vaccine will be administered by an intradermal microneedle device

NCT05803655UnknownNAHCG

Outcomes of 36 vs 38 Hour Intervals From Ovulation Trigger To Oocyte Pick-Up:A Multi-Center Randomized Controlled Trial

n=850ClinicalTrials.gov ↗

Start: 2023-04-27Completion: 2025-12

Study Interventions

• 36-hour duration between ovulation triggering and oocyte pick-up procedure

• 38-hour duration between ovulation triggering and oocyte pick-up procedure

NCT06790706RecruitingPh 2HCG

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

n=154ClinicalTrials.gov ↗

Start: 2025-10-01Completion: 2031-06

Study Interventions

• Patients will be treated with intravenous Domvanalimab at flat doses of 1600 mg + intravenous Zimberelimab at flat dose of 480 mg, administered every 4 weeks (Q4W), together with an induction treatment of intravenous FOLFOX-4 (Oxaliplatin 85 mg/m2 IV, L-folinic acid 200 mg/m2 IV, and fluorouracil 400 mg/m2 IV bolus on Day 1, fluorouracil 2400 mg/m2 IV continuous infusion over 46-48 hours starting on Day 1) given every 2 weeks, for 4 months (one cycle = 4 weeks).

• Patients will be treated with intravenous Domvanalimab at flat dose of 1200 mg + intravenous Zimberelimab at flat dose of 360 mg, administered every 3 weeks (Q3W, one cycle = 3 weeks).

NCT02940535UnknownNAHCG

Low Dose GnRHa Early Luteal Phase Down Regulation Versus GnRHa Ultra-short Protocol for Poor Ovarian Response

n=200ClinicalTrials.gov ↗

Start: 2016-12Completion: 2020-12

Study Interventions

• Diphereline (Triptorelin embonate)

• Decapeptyl (Triptorelin)

• human menopausal gonadotropin

• human chorionic gonadotropin

NCT02990403UnknownPh 4HCG

The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss

n=500ClinicalTrials.gov ↗

Start: 2014-10Completion: 2018-12-22

Study Interventions

• Heparin

• Immunoglobulin

• Aspirin

• Dydrogesterone

• Prednisone

NCT02402192TerminatedPh 4HCG

Type of Gonadotropin and Embryo Kinetics of Development

n=201ClinicalTrials.gov ↗

Start: 2015-04Completion: 2016-12

Study Interventions

• Corifollitropin alfa

NCT04797338UnknownPh 4HCG

Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders

n=100ClinicalTrials.gov ↗

Start: 2017-12-29Completion: 2021-09-30

Study Interventions

• Intranasal treatment with Nafarelin inhaler: 200 micrograms twice daily (a total of 400 micrograms/d; Synarel, Pfizer) on the evening after oocyte retrieval, which will be continued up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be stopped.

• A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.

NCT00805935CompletedPh 4HMG

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

n=110ClinicalTrials.gov ↗

Start: 2009-01Completion: 2010-09

Study Interventions

• 100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.

• 50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.

• 225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.

NCT02992808UnknownPh 4HMG

Androgenic Profile Following Controlled Ovarian Stimulation

n=100ClinicalTrials.gov ↗

Start: 2016-12Completion: 2020-01

Study Interventions

• HP-HMG

• recombinant gonadotropins

NCT00298025CompletedPh 4HMG

A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation

n=185ClinicalTrials.gov ↗

Start: 2003-09Completion: 2004-05

Study Interventions

• Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).

• The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.

• Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.

• Cetrotide® will be administered subcutaneously as 3 mg injection when the lead follicle is \>=14 mm till r-hCG day. If the subject did not achieve follicular maturation and did not receive r-hCG within 4 days, then the Cetrotide® will be administered at dose of 0.25 mg subcutaneously on successive days until r-hCG day.

• Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily when the lead follicle is \>=14 mm until r-hCG day.

NCT02940535UnknownNAHMG

Low Dose GnRHa Early Luteal Phase Down Regulation Versus GnRHa Ultra-short Protocol for Poor Ovarian Response

n=200ClinicalTrials.gov ↗

Start: 2016-12Completion: 2020-12

Study Interventions

• Diphereline (Triptorelin embonate)

• Decapeptyl (Triptorelin)

• human menopausal gonadotropin

• human chorionic gonadotropin

NCT01798862CompletedPh 2Ph 3HMG

Endometrial Injury and IVF Outcome Parameters in Patients With Failed IVF Cycles

n=100ClinicalTrials.gov ↗

Start: 2013-03Completion: 2016-06

Study Interventions

• Proceed to COH directly

• Endometrial injury by hysteroscopy or pipelle sampling

NCT04157725UnknownPh 4HMG

Mild Stimulation Protocol Using Clomiphene Citrate for Women With PCOS Undergoing in Vitro Fertilization

n=154ClinicalTrials.gov ↗

Start: 2023-06-01Completion: 2025-07-01

Study Interventions

• Group B (conventional stimulation protocol) will receive FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting on the 2nd day of menses. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.

• Group A (mild stimulation protocol) will receive oral Clomiphene Citrate (Clomid®) 150 mg/day for 5 days (starting on the 2nd of menses), followed by FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting from the 6th day of the menstrual cycle. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.

NCT06486870CompletedPh 3HMG

Comparison Between Two Ovulation Induction Therapies and LOD on Clinical Outcomes in CC-Resistant PCOS Women

n=183ClinicalTrials.gov ↗

Start: 2020-01-01Completion: 2024-01-31

Study Interventions

• 5 mg LE oral tablets are administered on the fifth day of menses and then every day for 5 days. Treatment is repeated for up to six cycles

• Laparoscopic ovarian drilling will be done according to the following: Electrocautery using a mixed current in monopolar electrosurgical needle will be into introduced through the ovarian ipsilateral parts and applied up to 4 point cauterisation of the ovarian capsule, each for 4 second, at 40 W and for a diameter of 3mm and a depth of 4 mm in the antimesentric surface . (Amer et al 2003, Sawant S et al 2019) ,the procedure will be applied for one ovary . The patient under the study will be followed up to six months of continuous marital life after the procedure

• Human menopausal gonadotrophin (hMG) is given starting on cycle day three in a dose of 75 IU alternate days. The aim of treatment is to achieve mono-ovulation. Monitoring of treatment is achieved by serial transvaginal ultrasound scanning every other day starting from cycle day nine. Size and number of follicles is recorded in patients follow up sheets. The dose of hMG is reviewed around stimulation day 10 and if follicular development is unsatisfactory, the dose is increased to 75 IU daily .If a good response is not achieved day16 ; the cycle is cancelled. A new cycle is commenced with a higher starting dose of hMG (75 IU per day). When one follicle reached a size of \> =18 mm a single dose of 10,000 IU human chorionic gonadotrophin (hCG, Pregnyl, Epifasi, Choriomon) is given.

NCT03703115WithdrawnNAHMG

The Effect of Fasting on ICSI Outcomes in Patients With Polycystic Ovary Syndrome

0ClinicalTrials.gov ↗

Start: 2018-10-14Completion: 2022-09-01

Study Interventions

• No food for 14 -16 hours with water intake and non caloric beverages then eating balanced meals over 8 to 10 hours

NCT03402620CompletedNAHMG

Poor Responders Infertile Patients -A Great Clinical Challenge

n=102ClinicalTrials.gov ↗

Start: 2018-01-11Completion: 2018-06-04

Study Interventions

• Human menopausal gonadotropin 75 IU ampoules start at cycle day 2

NCT07216742RecruitingPh 3HMG

Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.

n=659ClinicalTrials.gov ↗

Start: 2025-11-01Completion: 2028-11

Study Interventions

• daily subcutaneous injection

NCT01822340CompletedPh 2HGH

Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients

n=72ClinicalTrials.gov ↗

Start: 2011-10Completion: 2016-02

Study Interventions

• Once daily Genotropin

• Once weekly HM10560A

NCT00109733CompletedPh 3HGH

Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency

n=31ClinicalTrials.gov ↗

Start: 2005-01Completion: 2006-07

Study Interventions

• 0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.

• 0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.

NCT01934270UnknownNAHGH

Growth Hormone Secretion Following the Anaerobic Exercise

n=100ClinicalTrials.gov ↗

Start: 2014-05Completion: 2020-03-01

Study Interventions

• To evaluate the secretion of growth hormone in response to anaerobic exercise in children.

NCT01080755CompletedHGH

Metabolic Endocrinology and Growth Hormone in Adults

n=90ClinicalTrials.gov ↗

Start: 2003-12Completion: 2012-09

NCT01209416CompletedNAHGH

The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin

n=8ClinicalTrials.gov ↗

Start: 2012-06Completion: 2015-10

Study Interventions

• Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day

• Ghrelin infusion 4.2 ng/kg/min throughout the investigation day

NCT01020955CompletedPh 3HGH

Metabolic Effects of GH and IGF-I in Growth Hormone Deficient(GHD) and Diabetes and Impaired Glucose Tolerance(IGT)

n=14ClinicalTrials.gov ↗

Start: 2009-10Completion: 2011-11

Study Interventions

• NutropinAq (GH)(0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and Increlex (IGF-I) (15 µg/kg/d for 1 month, 30 µg/kg/d for 5 months)

NCT02068521TerminatedPh 2Ph 3HGH

Versartis Long-Term Safety Study of Somavaratan

n=385ClinicalTrials.gov ↗

Start: 2014-03-03Completion: 2017-11-17

Study Interventions

• Subcutaneous injection

NCT00212758CompletedPh 4HGH

A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood

n=17ClinicalTrials.gov ↗

Start: 2005-01Completion: 2010-05

Study Interventions

• Nutropin AQ

NCT01699308CompletedPh 1HGH

Growth Hormone and Brain Functioning After Traumatic Brain Injury

n=15ClinicalTrials.gov ↗

Start: 2009-12-01Completion: 2014-04-01

Study Interventions

• Genotropin

NCT07081282RecruitingNAHGH

Precision Stratification for Frailty and Cognitive Decline

n=252ClinicalTrials.gov ↗

Start: 2025-07-01Completion: 2027-05-31

Study Interventions

• Care4Senior mobile Application, Intensive Aerobic Resistance Training and Brain Health (CIRTAB)

• Participants will receive one time centre-based exercise health programme each week.

NCT05517122CompletedNANAD+

Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults

n=68ClinicalTrials.gov ↗

Start: 2022-07-12Completion: 2022-11-24

Study Interventions

• 1000 mg a day

• 500 mg a day

NCT07284225Not Yet RecruitingNANAD+

Acute Effects of Nicotinamide Riboside on Polysomnography-Measured Sleep Structure in Healthy Adults

n=20ClinicalTrials.gov ↗

Start: 2025-12-20Completion: 2026-12-30

Study Interventions

• A single oral dose of 600 mg NR, an NAD+ precursor compound, provided in capsule form. The dose and timing are standardized for all participants.

NCT07328100Not Yet RecruitingNANAD+

Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.

n=60ClinicalTrials.gov ↗

Start: 2026-01-16Completion: 2027-12-31

Study Interventions

• Subjects receive 7 consecutive days of intravenous infusion of Coenzyme I for injection.

NCT03568968CompletedPh 3NAD+

A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease

n=410ClinicalTrials.gov ↗

Start: 2020-05-06Completion: 2025-06-17

Study Interventions

• Nicotinamide Riboside 500mg administered two times a day. Given as capsules. Duration of the trial; 52 weeks.

NCT06425042RecruitingNANAD+

Nicotinamide Riboside Supplementation and Exercise Training to Promote Healthy Longevity

n=28ClinicalTrials.gov ↗

Start: 2024-03-01Completion: 2026-03

Study Interventions

• Participants will ingest 1g/d of NR orally during 12 weeks in parallel to a exercise training program

NCT03501433CompletedNANAD+

Effects of Nicotinamide Riboside on Metabolism and Vascular Function

n=16ClinicalTrials.gov ↗

Start: 2018-02-01Completion: 2019-12-01

Study Interventions

• 250 mg capsules 2x/day for 7 days

NCT04870866Active Not RecruitingPh 2NAD+

NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia

n=13ClinicalTrials.gov ↗

Start: 2019-06-05Completion: 2027-06-16

Study Interventions

• Two year intervention

NCT04407390WithdrawnPh 2NAD+

Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly

0ClinicalTrials.gov ↗

Start: 2020-06-01Completion: 2022-05-01

Study Interventions

• The patients will receive 1 g of nicotinamide riboside or placebo orally every morning for 14 days.

NCT04907110CompletedNANAD+

NR Supplementation and Exercise

n=30ClinicalTrials.gov ↗

Start: 2021-08-10Completion: 2022-12-07

Study Interventions

• During days 17-38 of the NR/placebo intake, participants will perform a 3-weeks supervised exercise training program with four \~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions.

• Participants in the NR supplementation + exercise group will undergo oral NR supplementation for 40 days. NiagenTM is the name for the dietary supplement containing NR (ChromaDex, Inc. Irvine, USA). The total dosage of NR per day will be 1000mg. This supplementation time of 40 days 1000mg/day

NCT03288623CompletedNANAD+

The Effects of Dark Chocolate Implementation in Elite Athletes

n=24ClinicalTrials.gov ↗

Start: 2017-09-25Completion: 2018-11-01

Study Interventions

• white or milk chocolate (\<35% cocoa) in tablet

• Dark chocolate (85% cocoa) in tablet

NCT01537549CompletedPh 1Ph 2L-Carnitine

Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy

n=11ClinicalTrials.gov ↗

Start: 2010-09-14Completion: 2015-04-07

Study Interventions

• alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months

NCT03008356CompletedPh 2Ph 3L-Carnitine

L-carnitine for Fatigue in COPD

n=33ClinicalTrials.gov ↗

Start: 2017-01Completion: 2018-02

Study Interventions

• Weekly health coaching calls lasting 10-15 minutes

• Oral L-carnitine to be taken twice daily for 8 weeks

NCT07303088CompletedNAL-Carnitine

Effects of L-carnitine and Coenzyme Q10 Supplementation on Oxidative Stress in Tunisian Hemodialysis Patients.

n=52ClinicalTrials.gov ↗

Start: 2024-06-17Completion: 2024-11-30

Study Interventions

• Oral administration of 1000mg of L-carnitine per day ( two oral capsules of 500mg) in L-carnitine group, and one placebo capsule identical to Coenzyme Q10.

• Oral administration of 300mg of Coenzyme Q10 per day (one oral capsule of 300mg) in Coenzyme Q10 group, with two placebo capsules identical to L-carnitine.

NCT04227782Active Not RecruitingL-Carnitine

MRI and Stable Isotope Tracer Studies for Detecting the Progression of Non-Alcoholic Steatohepatitis (NASH)

n=40ClinicalTrials.gov ↗

Start: 2020-03-01Completion: 2027-10-01

Study Interventions

• Stable Isotope study

• Magnetic Resonance Imaging

NCT01855373CompletedNAL-Carnitine

Comparing Blood Sugar Levels and Endothelial Function of PEAK ATP® With GlycoCarn®, PEAK ATP® and GlycoCarn® Supplements

n=60ClinicalTrials.gov ↗

Start: 2012-07Completion: 2016-04

Study Interventions

• PEAK ATP® (Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule): 2 capsules twice daily on an empty stomach

• PEAK ATP® with GlycoCarn® {Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule) and Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)}: 2 capsules twice daily on an empty stomach

• GlycoCarn® (Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule): 2 capsules twice daily on an empty stomach

NCT05817799CompletedPh 2Ph 3L-Carnitine

Impact of Hemodialysis on Plasma Carnitine Levels in Patients With End Stage Renal Disease

n=83ClinicalTrials.gov ↗

Start: 2023-01-01Completion: 2023-07-10

Study Interventions

• L-Carnitine 500mg oral thrice daily

• 1g IV L-Carnitine three times a week

NCT01461304No Longer AvailableL-Carnitine

Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism

ClinicalTrials.gov ↗

Study Interventions

• subjects will receive a modified diet containing triheptanoin (up to 2 grams/kg/24 hours; subjects who experience cardiomyopathy may receive doses up to 4 grams/kg/24 hours), or continued on their previously established triheptanoin dose; not to exceed RDA for fat, substituted for their MCT oil and/or natural fat. Study subjects will continue the triheptanoin-supplemented diet for a period of 12 months and then be able to continue into an indefinite extension phase in this compassionate use study. Laboratory evaluations will take place at two, six, and twelve months as well as every 12 months in the extension phase.

NCT05948124UnknownEARLY_Ph 1L-Carnitine

Carnitine Supplementation in Pediatric Hemodialysis Patients

n=40ClinicalTrials.gov ↗

Start: 2023-08-01Completion: 2024-03-01

Study Interventions

• Intravenous 5 ml of isotonic saline

• L-carnitine supplementation

NCT02598622TerminatedPh 2L-Carnitine

A Pilot Study Investigating the Effects of Acetyl-L-Carnitine and Vincristine-Induced Neuropathy in Pediatric Patients With ALL

n=8ClinicalTrials.gov ↗

Start: 2009-09Completion: 2016-01

Study Interventions

• Acetylcarnitine is taken 2 times a day for days 1 through 21.

NCT00809497CompletedPh 3L-Carnitine

A Clinical Study on Efficacy & Safety Profile of Propionyl-L-carnitine Tablets for Peripheral Arterial Diseases

n=239ClinicalTrials.gov ↗

Start: 2008-05Completion: 2011-01

Study Interventions

• 500mg tablets, oral administration of 2g daily

NCT01537549CompletedPh 1Ph 2L-Glutathione

Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy

n=11ClinicalTrials.gov ↗

Start: 2010-09-14Completion: 2015-04-07

Study Interventions

• alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months

NCT01467063CompletedNAL-Glutathione

Glutamine and Insulin Sensitivity in Type I Diabetes

n=13ClinicalTrials.gov ↗

Start: 2011-10Completion: 2013-07

Study Interventions

• Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a drink containing Glutamine (0.25 g/kg/dose). Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.

NCT02930031CompletedNAL-Glutathione

Redox Status and Immune Function

n=10ClinicalTrials.gov ↗

Start: 2015-01Completion: 2016-03

Study Interventions

• 20 mg//kg/day, orally, daily for eight days following exercise

NCT06417671CompletedNAL-Glutathione

The Effect of Postbiotics Supplementation on Exercise-induced Oxidative Stress.

n=16ClinicalTrials.gov ↗

Start: 2024-05-15Completion: 2024-08-30

Study Interventions

• The participants will consume one capsule per day.

NCT01541826CompletedNAL-Glutathione

Study of Chokeberry to Reduce Cardiovascular Disease Risk in Former Smokers

n=62ClinicalTrials.gov ↗

Start: 2012-02Completion: 2016-12

Study Interventions

• Consumption of 2 x 250 mg chokeberry extract capsules daily for 12 weeks.

• Chokeberry extract capsule, 2 x 250 mg, one-time dose.

NCT02316925WithdrawnNAL-Glutathione

GSH Supplementation on Cold/Flu Symptoms in Older Healthy Adults

0ClinicalTrials.gov ↗

Start: 2015-05Completion: 2015-05

Study Interventions

• 500 mg/day capsule taken in the morning

NCT05568316CompletedNAL-Glutathione

Impact of Immunonutrition on Nutritional Status in Colorectal Cancer Patients

n=50ClinicalTrials.gov ↗

Start: 2020-11-01Completion: 2022-02-10

Study Interventions

• Participants consumed oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before surgery. The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period.

• Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before and after surgery, in addition to their standard isocaloric diet. The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period.

NCT02530788CompletedPh 3L-Glutathione

High-dose Selenium Supplementation in Patients With Left Ventricular Assist

n=21ClinicalTrials.gov ↗

Start: 2015-08Completion: 2018-01

Study Interventions

• On the evening before operation the patient receives the first dosage of Selenium (300µg orally) orally as a pill. After induction of anaesthesia and before being put on the heart-lung-machine the patient receives 3000µg Selenium as sodium selenite (selenase® T) intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD).

NCT07303088CompletedNAL-Glutathione

Effects of L-carnitine and Coenzyme Q10 Supplementation on Oxidative Stress in Tunisian Hemodialysis Patients.

n=52ClinicalTrials.gov ↗

Start: 2024-06-17Completion: 2024-11-30

Study Interventions

• Oral administration of 1000mg of L-carnitine per day ( two oral capsules of 500mg) in L-carnitine group, and one placebo capsule identical to Coenzyme Q10.

• Oral administration of 300mg of Coenzyme Q10 per day (one oral capsule of 300mg) in Coenzyme Q10 group, with two placebo capsules identical to L-carnitine.

NCT01624792CompletedNAL-Glutathione

Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease (COPD): Aim 2

n=64ClinicalTrials.gov ↗

Start: 2011-10-25Completion: 2016-06-29

Study Interventions

• Dose: 7.0 g/day (= 7 capsules/day).

• Dose: 7.0 g/day (= 7 capsules/day = 3.5g EPA+DHA/day).

NCT07268508RecruitingNAVitamin B12

Impact of a Pro-diversity Gut Microbiota Diet After a Bariatric Surgery on Gut Microbiota, Eating Behaviour and Sensory Function

n=60ClinicalTrials.gov ↗

Start: 2025-11-05Completion: 2029-04-05

Study Interventions

• Nutritional counseling

NCT03544671CompletedNAVitamin B12

Effect of Vitamin D3 Supplementation in Children From 12 to 30 Months of Age.

n=220ClinicalTrials.gov ↗

Start: 2016-09-15Completion: 2017-12-21

Study Interventions

• Vitamin D

NCT03372447CompletedPh 4Vitamin B12

Megadose of Hydroxocobalamin for the Treatment of Pernicious Anemia

n=13ClinicalTrials.gov ↗

Start: 2017-12-27Completion: 2019-12-01

Study Interventions

• Single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg.

NCT00727571CompletedVitamin B12

LEARN-6™: A Prospective, Observational Nursing Home Study

n=815ClinicalTrials.gov ↗

Start: 2006-09Completion: 2008-07

Study Interventions

• This is a non-interventional, observational study; no investigational product is being used

NCT07021248RecruitingPh 4Vitamin B12

A Randomized Controlled Trial Evaluating the Impact of Procedure-Specific Bariatric Supplements on Micronutrient Status and Vitamin B6 Hypervitaminosis Following Metabolic and Bariatric Surgery

n=249ClinicalTrials.gov ↗

Start: 2025-06-15Completion: 2026-06

Study Interventions

• Participants will receive a specialized Elan bariatric supplement matched to the type of MBS they undergo. Elan Compass for RYGB addresses the distinct micronutrient absorption profiles and physiological alterations associated with this surgical procedure. Importantly, all formulations contain a standardized dose of vitamin B6 of 400 micrograms, facilitating valid comparisons of postoperative B6 levels across procedures.

• Participants will receive a specialized Elan bariatric supplement matched to the type of MBS they undergo. Elan Believe for SG addresses the distinct micronutrient absorption profiles and physiological alterations associated with this surgical procedure. Importantly, all formulations contain a standardized dose of vitamin B6 of 400 micrograms, facilitating valid comparisons of postoperative B6 levels across procedures.

• Participants will receive a specialized Elan bariatric supplement matched to the type of MBS they undergo. Elan Supreme for OAGB addresses the distinct micronutrient absorption profiles and physiological alterations associated with this surgical procedure. Importantly, all formulations contain a standardized dose of vitamin B6 of 400 micrograms, facilitating valid comparisons of postoperative B6 levels across procedures.

NCT07050342Not Yet RecruitingNAVitamin B12

Evaluation of the Specialized Clinic for Nutrition and Mental Health: A Pilot Study

n=84ClinicalTrials.gov ↗

Start: 2025-12-01Completion: 2028-12-01

Study Interventions

• This intervention involves personalized, nutrition-focused care provided in a specialized outpatient clinic for individuals with psychosomatic and mental health conditions. The care model integrates nutritional counseling, education on gut-brain interactions, and patient-centered support to promote psychological well-being and reduce stress. No experimental drugs or diets are administered. Instead, the intervention focuses on individualized recommendations based on clinical assessments and ongoing routine laboratory markers (e.g., inflammatory markers, vitamin levels). Participants also receive guidance aimed at improving dietary habits and resilience within a biopsychosocial framework. The intervention is part of regular clinical care and not blinded or randomized.

NCT04170205UnknownVitamin B12

Causes Associated With Small Fiber Neuropathy (SFN).

n=450ClinicalTrials.gov ↗

Start: 2019-11-15Completion: 2020-04-30

NCT05211375RecruitingPh 3Vitamin B12

Comparisons of Metabolic Effect of Sleeve Gastrectomy With Duodenojejunal Bypass and Sleeve Gastrectomy (MEDUSA): A Multicenter Randomized Controlled Trial

n=130ClinicalTrials.gov ↗

Start: 2022-01-03Completion: 2036-01-03

Study Interventions

• Sleeve gastrectomy will be performed in the same manner as in the SG group. DJB will be performed by transection of the duodenum and bypassing 250 cm of the proximal jejunum. The handsewn suture will be used for duodenojejunal anastomosis, and the size of anastomosis will be 1.5 - 2 cm. Single anastomosis will be performed rather than Roux-en-Y fashion.

• Sleeve gastrectomy will be performed using 36-38 Fr bougie. The initial stapling start point will be between 4-6 cm from the pylorus, and the last stapling will be performed at least 1 cm away from His angle. The height of the automatic stapler will be selected based on the researcher's discretion.

NCT06175130CompletedVitamin B12

Cross-sectional Dietary Intake Survey on Ivorian School-Aged Children and Women of Reproductive Age

n=846ClinicalTrials.gov ↗

Start: 2021-02-01Completion: 2021-02-28

NCT04740346RecruitingNAVitamin B12

Survival Rates and Quality of Life According to Follow-up Period After Gastrectomy for Gastric Cancer (STOFOLUP)

n=886ClinicalTrials.gov ↗

Start: 2021-07-05Completion: 2026-06-30

Study Interventions

• CT will be performed every 3 months after gastrectomy in the 3-months follow-up group. CT will be performed every 6 months after gastrectomy in the 6 months follow-up group.

NCT05198362WithdrawnPh 2Tesofensine

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

0ClinicalTrials.gov ↗

Start: 2021-12-28Completion: 2022-12-09

Study Interventions

• Fixed-dose combination

NCT00481104CompletedPh 2Tesofensine

Evaluation of Long Term Safety of Tesofensine in Patients With Obesity

n=140ClinicalTrials.gov ↗

Start: 2007-05Completion: 2008-11

Study Interventions

• Tesofensine

NCT03845075CompletedPh 2Tesofensine

48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)

n=21ClinicalTrials.gov ↗

Start: 2019-02-25Completion: 2020-10-16

Study Interventions

• During Part 1 subjects will be randomized to treatment with co-administration of 0.5 mg tesofensine/50mg metoprolol (active medication)

NCT05147415WithdrawnPh 2Tesofensine

Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)

0ClinicalTrials.gov ↗

Start: 2021-11-11Completion: 2022-12-09

Study Interventions

• Fixed-dose combination

NCT00428415CompletedPh 1Ph 2Tesofensine

Effect of Tesofensine on Energy Balance in Humans.